These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36174377)

  • 21. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
    McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
    J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.
    Miolo G; Ash A; Buonadonna A; Lo Re G; Torrisi E; Cervo S; Santeufemia DA; Tuzi A; Canzonieri V
    Cancer Biol Ther; 2014; 15(11):1439-43. PubMed ID: 25482943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
    Takamatsu D; Kiyozawa D; Kohashi K; Kinoshita F; Toda Y; Ishihara S; Eto M; Oda Y
    Pathol Res Pract; 2023 Apr; 244():154423. PubMed ID: 36989848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
    Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
    Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal cell carcinoma with sarcomatoid and rhabdoid features: a clinico-pathological series of 74 cases].
    Queipo FJ; Panizo A; Sola JJ; Beorlegui C; Velis JM; Dolezal P; Pardo-Mindán J
    An Sist Sanit Navar; 2018 Aug; 41(2):191-199. PubMed ID: 30063035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features.
    Kuroda N; Tamura M; Hamaguchi N; Mikami S; Pan CC; Brunelli M; Martignoni G; Hes O; Michal M; Lee GH
    Ann Diagn Pathol; 2011 Dec; 15(6):462-6. PubMed ID: 21036640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.
    Delahunt B; Cheville JC; Martignoni G; Humphrey PA; Magi-Galluzzi C; McKenney J; Egevad L; Algaba F; Moch H; Grignon DJ; Montironi R; Srigley JR;
    Am J Surg Pathol; 2013 Oct; 37(10):1490-504. PubMed ID: 24025520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Succinate Dehydrogenase Deficient Renal Cell Carcinoma With Sarcomatoid and Rhabdoid Features-A Diagnostic Dilemma.
    Ajmal N; Lallas CD; McCue P; Li L
    Int J Surg Pathol; 2024 Dec; 32(8):1508-1513. PubMed ID: 38311902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.
    Esnakula AK; Naab TJ; Green W; Shokrani B
    BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23608849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarcomatoid renal cell carcinoma: biology, natural history and management.
    Blum KA; Gupta S; Tickoo SK; Chan TA; Russo P; Motzer RJ; Karam JA; Hakimi AA
    Nat Rev Urol; 2020 Dec; 17(12):659-678. PubMed ID: 33051619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
    Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
    Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
    Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
    Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.
    Molina AM; Tickoo SK; Ishill N; Trinos MJ; Schwartz LH; Patil S; Feldman DR; Reuter VE; Russo P; Motzer RJ
    Am J Clin Oncol; 2011 Oct; 34(5):454-9. PubMed ID: 21127411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].
    Kristiansen G; Delahunt B; Srigley JR; Lüders C; Lunkenheimer JM; Gevensleben H; Thiesler T; Montironi R; Egevad L
    Pathologe; 2015 May; 36(3):310-6. PubMed ID: 25398389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
    Uemura M; Nakaigawa N; Sassa N; Tatsugami K; Harada K; Yamasaki T; Matsubara N; Yoshimoto T; Nakagawa Y; Fukuyama T; Oya M; Shinohara N; Uemura H; Tsuzuki T
    Int J Clin Oncol; 2021 Nov; 26(11):2073-2084. PubMed ID: 34291367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503.
    Jay R; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
    Urol Oncol; 2017 Mar; 35(3):117-118. PubMed ID: 28159495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.